News coverage about Ophthotech (NASDAQ:OPHT) has trended somewhat positive on Tuesday, according to Accern Sentiment. The research group ranks the sentiment of news coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Ophthotech earned a media sentiment score of 0.21 on Accern’s scale. Accern also gave press coverage about the biopharmaceutical company an impact score of 47.4040570770957 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.
These are some of the media headlines that may have effected Accern Sentiment’s scoring:
A number of research firms have recently weighed in on OPHT. JPMorgan Chase & Co. cut shares of Ophthotech from a “neutral” rating to an “underweight” rating in a report on Monday. TheStreet cut shares of Ophthotech from a “c” rating to a “d+” rating in a report on Friday, March 2nd. Zacks Investment Research cut shares of Ophthotech from a “strong-buy” rating to a “hold” rating in a report on Wednesday, March 7th. Finally, ValuEngine cut shares of Ophthotech from a “buy” rating to a “hold” rating in a research note on Thursday, March 1st. One equities research analyst has rated the stock with a sell rating and three have assigned a hold rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $3.63.
Shares of Ophthotech (NASDAQ:OPHT) opened at $2.99 on Tuesday. The company has a market cap of $110.26, a P/E ratio of 0.94 and a beta of 1.42. Ophthotech has a 12 month low of $2.24 and a 12 month high of $3.72.
Ophthotech (NASDAQ:OPHT) last released its earnings results on Tuesday, February 27th. The biopharmaceutical company reported ($0.26) EPS for the quarter, topping analysts’ consensus estimates of ($0.58) by $0.32. Ophthotech had a net margin of 26.69% and a negative return on equity of 230.07%. During the same period in the previous year, the firm posted ($1.86) earnings per share. research analysts expect that Ophthotech will post -1.69 EPS for the current year.
In other Ophthotech news, insider David R. Guyer sold 16,520 shares of the firm’s stock in a transaction that occurred on Tuesday, January 2nd. The shares were sold at an average price of $3.19, for a total transaction of $52,698.80. Following the completion of the transaction, the insider now directly owns 50,494 shares of the company’s stock, valued at approximately $161,075.86. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Glenn Sblendorio sold 8,089 shares of the firm’s stock in a transaction that occurred on Tuesday, January 2nd. The stock was sold at an average price of $3.19, for a total transaction of $25,803.91. Following the transaction, the chief executive officer now directly owns 44,584 shares of the company’s stock, valued at $142,222.96. The disclosure for this sale can be found here. Insiders sold a total of 34,971 shares of company stock valued at $111,481 over the last quarter. 2.00% of the stock is owned by company insiders.
COPYRIGHT VIOLATION WARNING: “Ophthotech (OPHT) Receives Media Impact Rating of 0.21” was reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this piece of content on another publication, it was illegally stolen and reposted in violation of US & international copyright law. The correct version of this piece of content can be viewed at https://www.dispatchtribunal.com/2018/03/20/ophthotech-opht-receives-media-impact-rating-of-0-21.html.
Ophthotech Company Profile
Ophthotech Corporation is a biopharmaceutical company. The Company is engaged in the development of therapeutics to treat ophthalmic diseases, with a focus on diseases of the back of the eye. Its primary focus is developing therapeutics for age-related macular degeneration (AMD), which is a disorder of the central portion of the retina, known as the macula, that may result in blindness.
Receive News & Ratings for Ophthotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ophthotech and related companies with MarketBeat.com's FREE daily email newsletter.